Herpes zoster development in living kidney transplant recipients receiving low-dose rituximab

IF 1.8 3区医学 Q3 UROLOGY & NEPHROLOGY

International Journal of Urology Pub Date : 2024-10-07 DOI:10.1111/iju.15600

Hayato Nishida, Hiroki Fukuhara, Satoshi Takai, Takaaki Nawano, Tomohiro Takehara, Takafumi Narisawa, Hidenori Kanno, Mayu Yagi, Atsushi Yamagishi, Sei Naito, Norihiko Tsuchiya

{"title":"Herpes zoster development in living kidney transplant recipients receiving low-dose rituximab","authors":"Hayato Nishida, Hiroki Fukuhara, Satoshi Takai, Takaaki Nawano, Tomohiro Takehara, Takafumi Narisawa, Hidenori Kanno, Mayu Yagi, Atsushi Yamagishi, Sei Naito, Norihiko Tsuchiya","doi":"10.1111/iju.15600","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>We evaluated whether a history of low-dose rituximab treatment affected herpes zoster development after living kidney transplantation.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We enrolled 103 living kidney transplant recipients. Patients were divided into two groups according to their history of rituximab treatment; rituximab was administered to 50 living kidney transplant recipients. We assessed the difference in herpes zoster events between the two groups and determined the risk factors for herpes zoster using multivariate regression analysis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The total dose of rituximab in each kidney transplant recipient who received rituximab therapy was 200–400 mg. The rate of herpes zoster events after transplantation in recipients who received rituximab therapy (4 of 50, 8%) was not higher than that in recipients who did not receive rituximab (9 of 53, 17%) (<i>p</i> = 0.238). Herpes zoster-free survival did not significantly differ between the two groups (<i>p</i> = 0.409). In the multivariate regression analysis, the association between varicella zoster vaccination before transplantation and herpes zoster events after transplantation was confirmed, whereas rituximab therapy was not associated with herpes zoster events.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Low-dose rituximab therapy in kidney transplant recipients did not influence herpes zoster development after transplantation. Varicella zoster vaccination before transplantation may play an important role in preventing herpes zoster after transplantation.</p>\n </section>\n </div>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"32 1","pages":"88-93"},"PeriodicalIF":1.8000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729987/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/iju.15600","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

We evaluated whether a history of low-dose rituximab treatment affected herpes zoster development after living kidney transplantation.

Methods

We enrolled 103 living kidney transplant recipients. Patients were divided into two groups according to their history of rituximab treatment; rituximab was administered to 50 living kidney transplant recipients. We assessed the difference in herpes zoster events between the two groups and determined the risk factors for herpes zoster using multivariate regression analysis.

Results

The total dose of rituximab in each kidney transplant recipient who received rituximab therapy was 200–400 mg. The rate of herpes zoster events after transplantation in recipients who received rituximab therapy (4 of 50, 8%) was not higher than that in recipients who did not receive rituximab (9 of 53, 17%) (p = 0.238). Herpes zoster-free survival did not significantly differ between the two groups (p = 0.409). In the multivariate regression analysis, the association between varicella zoster vaccination before transplantation and herpes zoster events after transplantation was confirmed, whereas rituximab therapy was not associated with herpes zoster events.

Conclusions

Low-dose rituximab therapy in kidney transplant recipients did not influence herpes zoster development after transplantation. Varicella zoster vaccination before transplantation may play an important role in preventing herpes zoster after transplantation.

Abstract Image

查看原文本刊更多论文

接受低剂量利妥昔单抗治疗的活体肾移植受者出现带状疱疹。

目的我们评估了低剂量利妥昔单抗治疗史是否会影响活体肾移植后带状疱疹的发生：我们招募了 103 名活体肾移植受者。根据利妥昔单抗治疗史将患者分为两组；50 名活体肾移植受者接受了利妥昔单抗治疗。我们评估了两组带状疱疹事件的差异，并使用多变量回归分析确定了带状疱疹的风险因素：结果：每位接受利妥昔单抗治疗的肾移植受者的利妥昔单抗总剂量为 200-400 毫克。接受利妥昔单抗治疗的受者在移植后发生带状疱疹的比例（50 例中有 4 例，8%）不高于未接受利妥昔单抗治疗的受者（53 例中有 9 例，17%）（P = 0.238）。两组无带状疱疹存活率无明显差异（p = 0.409）。在多变量回归分析中，移植前接种水痘带状疱疹疫苗与移植后带状疱疹事件之间的关联得到了证实，而利妥昔单抗治疗与带状疱疹事件无关：结论：肾移植受者接受低剂量利妥昔单抗治疗不会影响移植后带状疱疹的发生。移植前接种水痘带状疱疹疫苗可能对预防移植后带状疱疹起到重要作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Urology 医学-泌尿学与肾脏学

CiteScore

4.70

自引率

11.50%

发文量

340

审稿时长

3 months

期刊介绍： International Journal of Urology is the official English language journal of the Japanese Urological Association, publishing articles of scientific excellence in urology. Submissions of papers from all countries are considered for publication. All manuscripts are subject to peer review and are judged on the basis of their contribution of original data and ideas or interpretation.